Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ngm Biopharmaceuticals Inc (NGM)

Ngm Biopharmaceuticals Inc (NGM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,079,144
  • Shares Outstanding, K 66,655
  • Annual Sales, $ 108,665 K
  • Annual Income, $ -493 K
  • 60-Month Beta N/A
  • Price/Sales 8.96
  • Price/Cash Flow N/A
  • Price/Book 3.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.13 +7.01%
on 02/07/20
18.79 -13.85%
on 01/24/20
-2.23 (-12.11%)
since 01/21/20
3-Month
14.21 +13.97%
on 11/22/19
20.50 -21.02%
on 12/18/19
+1.86 (+12.98%)
since 11/21/19

Most Recent Stories

More News
Horizon Discovery Grants a Multi-Product Use License of its GS knockout CHO K1 Cell Line to NGM Bio

Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that...

HZNQF : 2.1500 (-4.44%)
NGM : 16.19 (-0.31%)
New Medical Device That is Proving Effective Against the Worlds Toughest Viruses, Including: Ebola, Hep C, HIV, West Nile and Smallpox Wins FDA Designation "Breakthrough Device"

USA News Group - A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that may also suppress Zika virus infection. Zika virus disease...

AEMD : 2.50 (-3.10%)
NGM : 16.19 (-0.31%)
EBS : 65.94 (+2.11%)
SIGA : 4.73 (-4.83%)
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors...

NGM : 16.19 (-0.31%)
NVTA : 23.10 (-3.02%)
NGM Biopharmaceuticals Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.

NGM : 16.19 (-0.31%)
NGM Biopharmaceuticals: 3Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Tuesday reported a loss of $10.9 million in its third quarter.

NGM : 16.19 (-0.31%)
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 65.63 (+0.71%)
LLY : 142.04 (+0.03%)
ACAD : 45.13 (+0.67%)
CHRS : 22.53 (+0.13%)
CELG : 108.24 (+0.10%)
BIIB : 336.71 (+0.02%)
INCY : 80.89 (-2.27%)
ADPT : 34.16 (+1.07%)
ALEC : 30.47 (+1.97%)
NGM : 16.19 (-0.31%)
TAK : 18.79 (+1.18%)
5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

ASND : 141.90 (-2.21%)
SAGE : 69.53 (-1.21%)
NGM : 16.19 (-0.31%)
EYEN : 4.34 (-2.26%)
ACIU : 8.41 (+0.12%)
Genesis Healthcare (GEN) to Post Q3 Earnings: What to Expect

Genesis Healthcare's (GEN) third-quarter results are likely to reflect weak revenues, partially offset by same store facility growth and lower expenses.

CBM : 59.99 (unch)
GEN : 1.73 (+1.17%)
ACB : 1.67 (-0.60%)
NGM : 16.19 (-0.31%)
Will NGM Biopharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.

NGM : 16.19 (-0.31%)
NGM Biopharmaceuticals: 2Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Monday reported a loss of $7.7 million in its second quarter.

NGM : 16.19 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NGM with:

Business Summary

NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc....

See More

Key Turning Points

2nd Resistance Point 17.07
1st Resistance Point 16.63
Last Price 16.19
1st Support Level 15.87
2nd Support Level 15.54

See More

52-Week High 20.50
Last Price 16.19
Fibonacci 61.8% 16.03
Fibonacci 50% 14.66
Fibonacci 38.2% 13.28
52-Week Low 8.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar